Literature DB >> 17003774

Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.

C Cai1, J Omwancha, C-L Hsieh, L Shemshedini.   

Abstract

Multidrug resistance-associated proteins (MRPs) may mediate multidrug resistance in tumor cells. Using a gene array analysis, we have identified MRP4 as an androgen receptor (AR)-regulated gene. Dihydrotestosterone induced MRP4 expression in both androgen-dependent and -independent LNCaP cells, whereas there was little detectable expression in PC-3 or normal prostate epithelial cells. Disruption of MRP4 expression renders LNCaP cells more sensitive to the cytotoxic effects of methotrexate but not etoposide. Analysis of human tissues showed detectable MRP4 expression only in metastatic prostate cancer. These results suggest that AR induction of MRP4 mediates resistance of PC cells to nucleotide-based chemotherapeutic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003774     DOI: 10.1038/sj.pcan.4500912

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  21 in total

1.  Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer.

Authors:  Yun-Fei Li; Hui-Hua Ji; Zheng-Long Zhang; Tao-Tao Zhang; Wei Gan; Shao-Feng Zhang
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

2.  Direct and coordinate regulation of ATP-binding cassette transporter genes by Myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells.

Authors:  Antonio Porro; Michelle Haber; Daniel Diolaiti; Nunzio Iraci; Michelle Henderson; Samuele Gherardi; Emanuele Valli; Marcia A Munoz; Chengyuan Xue; Claudia Flemming; Manfred Schwab; Jason H Wong; Glenn M Marshall; Giuliano Della Valle; Murray D Norris; Giovanni Perini
Journal:  J Biol Chem       Date:  2010-03-16       Impact factor: 5.157

3.  Developing Enhanced Blood-Brain Barrier Permeability Models: Integrating External Bio-Assay Data in QSAR Modeling.

Authors:  Wenyi Wang; Marlene T Kim; Alexander Sedykh; Hao Zhu
Journal:  Pharm Res       Date:  2015-04-11       Impact factor: 4.200

4.  Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.

Authors:  Clay E S Comstock; Michael A Augello; Matthew J Schiewer; Jason Karch; Craig J Burd; Adam Ertel; Erik S Knudsen; Walter J Jessen; Bruce J Aronow; Karen E Knudsen
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

5.  Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.

Authors:  Tian Zhou; Minlu Hu; Andrew Pearlman; Lisa C Rohan
Journal:  Biochem Pharmacol       Date:  2016-07-21       Impact factor: 5.858

Review 6.  Targeting inflammation: multiple innovative ways to reduce prostaglandin E₂.

Authors:  Jessica K Norberg; Earlphia Sells; Hui-Hua Chang; Srinivas R Alla; Shuxing Zhang; Emmanuelle J Meuillet
Journal:  Pharm Pat Anal       Date:  2013-03

7.  TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins.

Authors:  Meenakshi Bhansali; Jun Zhou; Lirim Shemshedini
Journal:  Mol Endocrinol       Date:  2015-12-09

8.  Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression.

Authors:  Matteo Montani; Thomas Hermanns; Thomas Herrmanns; Michael Müntener; Peter Wild; Tullio Sulser; Glen Kristiansen
Journal:  Virchows Arch       Date:  2013-03-16       Impact factor: 4.064

9.  Novel Symmetrical Cage Compounds as Inhibitors of the Symmetrical MRP4-Efflux Pump for Anticancer Therapy.

Authors:  David Kreutzer; Henry Döring; Peter Werner; Christoph A Ritter; Andreas Hilgeroth
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

10.  ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma.

Authors:  Tony Huynh; Murray D Norris; Michelle Haber; Michelle J Henderson
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.